Prostate Specific Antigen Regression and Progression after Androgen Deprivation for Localized and Metastatic Prostate Cancer
- 1 June 1995
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 153 (6) , 1860-1865
- https://doi.org/10.1016/s0022-5347(01)67332-4
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancerCancer, 1992
- The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate CancerJournal of Urology, 1992
- Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell lineEndocrinology, 1992
- Prostatic Specific Antigen and the Prediction of Prognosis in Metastatic Prostatic CancerCancer, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. IV. Anti-Androgen Treated PatientsJournal of Urology, 1989
- Differences in Values Obtained with 2 Assays of Prostate Specific AntigenJournal of Urology, 1988
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- Histologic Grading of Primary Prostatic Cancer: A New Approach to an Old ProblemJournal of Urology, 1980